Postpartum Depression: Causes, Screening, and New Treatments

A Condition That Affects Far More Than Mothers

Postpartum depression (PPD) strikes approximately one in seven new mothers — roughly 600,000 women in the United States annually — making it the most common complication of childbirth. Yet epidemiological data from 2016–2022 show that up to 40 percent of cases remain undiagnosed at the 6-week postpartum visit. The consequences extend beyond the individual: untreated maternal PPD is associated with impaired mother-infant bonding, delayed infant cognitive and language development, and increased risk of childhood behavioral problems. The economic burden in the U.S. was estimated at $14.2 billion in a 2020 analysis spanning the first five years of childhood.

Distinguishing PPD from Baby Blues and Postpartum Psychosis

Three distinct postpartum mental health conditions exist on a severity spectrum. Baby blues — transient emotional lability, tearfulness, and anxiety — affect 50–80 percent of new mothers, peak at day 3–5 postpartum when progesterone withdrawal is steepest, and resolve within 2 weeks. Baby blues require no treatment beyond support. Postpartum psychosis is rare (1–2 per 1,000 deliveries), involves psychotic symptoms, hallucinations, and confusion, typically onset within days of delivery, and constitutes a psychiatric emergency. PPD sits between these extremes.

DSM-5 classifies PPD as a Major Depressive Episode with peripartum onset — symptoms meeting full MDD criteria beginning during pregnancy or within four weeks of delivery, though clinicians widely apply the diagnosis up to 12 months postpartum. Symptoms include depressed mood, loss of interest, fatigue, sleep disturbance beyond newborn-related disruption, worthlessness, impaired concentration, and in severe cases, thoughts of self-harm or harm to the infant.

The Hormonal Withdrawal Trigger

During pregnancy, placental production of allopregnanolone — a neurosteroid metabolite of progesterone — reaches levels up to 20 times higher than normal luteal phase concentrations. Allopregnanolone is a potent positive modulator of GABA-A receptors, the brain's primary inhibitory receptors. It has anxiolytic, sedative, and mood-stabilizing effects.

At delivery, allopregnanolone levels plummet precipitously within 24–48 hours as the placenta is expelled. In women who develop PPD, this withdrawal appears to trigger a pathological GABA-A receptor dysregulation. Research by Dr. Samantha Meltzer-Brody and colleagues at the University of North Carolina demonstrated that women with PPD show blunted GABA-A receptor sensitivity compared to women without PPD after equivalent hormonal shifts. The vulnerability is not to the hormone level itself but to the sensitivity of receptors to its change.

The Edinburgh Postnatal Depression Scale

The Edinburgh Postnatal Depression Scale (EPDS), developed by Cox, Holden, and Sagovsky in 1987, is the most widely validated screening tool for PPD globally. It consists of 10 self-report items, each scored 0–3, yielding a maximum score of 30. A cutoff of 10 or above is typically used in clinical practice, giving sensitivity of 86 percent and specificity of 78 percent for major depression in the postpartum period. The USPSTF (U.S. Preventive Services Task Force) recommends screening all postpartum women.

Question 10 ("The thought of harming myself has occurred to me") is scored separately; any score above 0 on this item triggers immediate clinical assessment regardless of total score.

FDA-Approved Treatments: Brexanolone and Zuranolone

Until 2019, PPD had no FDA-approved pharmacotherapy distinct from general antidepressants — SSRIs and SNRIs, which work through serotonergic pathways, take 4–6 weeks to show benefit and were repurposed from general depression data. Two neuroactive steroid GABA-A modulators have since changed this landscape.

• Brexanolone (Zulresso, FDA approved 2019): A synthetic form of allopregnanolone delivered by 60-hour continuous intravenous infusion. In Phase III trials (Kanes et al., NEJM 2017), brexanolone produced a mean reduction in Hamilton Depression Rating Scale (HAMD-17) score of 21 points versus 8.8 points for placebo at 60 hours. Response rate was 75 percent. Administration requires certified healthcare facility monitoring (risk of excessive sedation); cost is approximately $34,000 per infusion course.
• Zuranolone (Zurzuvae, FDA approved August 2023): An oral neuroactive steroid GABA-A modulator taken once daily for 14 days. Phase III SKYLARK trial showed significant reduction in HAMD-17 scores versus placebo within 3 days, with benefits persisting at Day 45 despite the short treatment course. FDA approval covers PPD and major depressive disorder — the first oral treatment with a 14-day course. Contraindicated in breastfeeding due to insufficient data.

Paternal Postpartum Depression

PPD is not exclusively maternal. A 2010 meta-analysis by James Paulson and Sharnail Bazemore in JAMA found that 10.4 percent of fathers experience depression in the perinatal period (pregnancy through 12 months postpartum) — almost double the male population baseline rate. Paternal PPD peaks at 3–6 months postpartum, later than maternal PPD. It is associated with maternal PPD (an independent risk factor), sleep deprivation, financial stress, and partner relationship strain. Paternal PPD is associated with reduced father-child interaction quality and increased behavioral problems in children, independently of maternal mental health. Screening tools validated for fathers include the EPDS (same cutoff thresholds) and the Gotland Male Depression Scale.

This article is for informational purposes only. Consult a qualified healthcare professional.